Challenge of Effectively Using Erythropoiesis-Stimulating Agents and Intravenous Iron

American Journal of Kidney Diseases

Volumn 52, Issue 6 SUPPL. 1, 2008, Pages

  Kapoian, Toros ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Anemia of chronic kidney disease; erythropoiesis stimulating agent; intravenous iron

Indexed keywords

ERYTHROPOIETIN; FERRIC GLUCONATE; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; HEMODIALYSIS; HUMAN; REVIEW;

ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FERRIC COMPOUNDS; GUIDELINES AS TOPIC; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 55749101564     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.09.004     Document Type: Review

References (31)

1. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
2. Drüeke T.B., Locatelli F., Clyne N., et al., CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
3. Singh A.K., Szczech L., Tang K.L., et al., CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
4. US Food and Drug Administration and Center for Drug Evaluation and Research. Information for Healthcare Professionals: Erythropoiesis Stimulating Agents (ESA). http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.htm Accessed February 25, 2008
5. National Kidney Foundation. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease, 2007 Update of Hemoglobin Target. Am J Kidney Dis 50 (2007) 471-530
6. Centers for Medicare & Medicaid Services. CMS Manual System. Pub 100-04 Medicare Claims Processing. Transmittal 1307. Change Request 5700. 7-20-2007. http://www.cms.hhs.gov/Transmittals/Downloads/R1307CP.pdf Accessed January 3, 2008
7. US Renal Data System. USRDS 2007 Annual Data Report (2007), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
8. FDA. Aranesp (darbepoetin alfa) for injection: Prescribing information (March 2008), US Food and Drug Administration (USFDA), Silver Spring, MD
9. FDA. Procrit (Epoetin alfa) for injection: Prescribing information (March 2008), US Food and Drug Administration (USFDA), Silver Spring, MD
10. Fishbane S., and Berns J.S. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68 (2005) 1337-1343
11. Yang W., Israni R.K., Brunelli S.M., Joffe M.M., Fishbane S., and Feldman H.I. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 18 (2007) 3164-3170
12. Ebben J.P., Gilbertson D.T., Foley R.N., and Collins A.J. Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 1 (2006) 1205-1210
13. Gilbertson D.T., Ebben J.P., Foley R.N., Weinhandl E.D., Bradbury B.D., and Collins A.J. Hemoglobin level variability: Associations with mortality. Clin J Am Soc Nephrol 3 (2008) 133-138
14. Portolés J., López-Gómez J.M., and Aljama P. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: The MAR Study. Nephrol Dial Transplant 22 (2007) 500-507
15. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 suppl 3 (2006) S11-S145
16. Fishbane S., and Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2 (2007) 1274-1282
17. Petroff S. Evaluating traditional iron measures and exploring new options for patients on hemodialysis. Nephrol Nurs J 32 (2005) 65-73
18. National Kidney Foundation. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 37 suppl 1 (2001) S182-S238
19. Gastaldello K., Vereerstraeten A., Nzame-Nze T., et al. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 10 suppl 6 (1995) S44-S47
20. Tarng D.C., Wei Y.H., Huang T.P., et al. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int 55 (1999) 2477-2486
21. Attallah N., Osman-Malik Y., Frinak S., and Besarab A. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 47 (2006) 644-654
22. Locatelli F., Aljama P., Barany P., et al. Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19 Suppl 2 (2004) ii1-ii47
23. Lin J.L., Chang M.Y., Tan D.T., and Leu M.L. Short-term small-dose intravenous iron trial to detect functional iron deficiency in dialysis patients. Am J Nephrol 21 (2001) 91-97
24. Wish J.B. Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 1 suppl 1 (2006) S4-S8
25. Regidor D.L., Kopple J.D., Kovesdy C.P., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17 (2006) 1181-1191
26. US Food and Drug Administration and Center for Drug Evaluation and Research. Questions and Answers for Erythropoiesis-Stimulating Agents (ESAs) Labeling Changes. http://www.fda.gov/CDER/drug/infopage/RHE/qa2007.htm Accessed February 25, 2008
27. Centers for Medicare & Medicaid Services. 2005 Annual Report, End-Stage Renal Disease Clinical Performance Measures Project (2005), Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards and Quality, Baltimore, MD
28. Coyne D.W., Kapoian T., Suki W., et al., DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18 (2007) 975-984
29. Kapoian T., O'Mara N.B., Singh A.K., et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19 (2008) 372-379
30. Warady B.A., Zobrist R.H., Wu J., Finan E., and Ferrlecit Pediatric Study Group. Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol 20 (2005) 1320-1327
31. Nissenson A.R., Lindsay R.M., Swan S., Seligman P., and Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am J Kidney Dis 33 (1999) 471-482